ArticleThe Journal of thoracic and cardiovascular surgery2023
Neoadjuvant therapy does not increase postoperative morbidity of sleeve lobectomy in locally advanced non-small cell lung cancer.
Article in The Journal of thoracic and cardiovascular surgery, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 18 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
18 citing papers in PubMed, 22 citations in OpenAlex.
- Impact of Neoadjuvant Immunotherapy Combined with Chemotherapy on Surgical Margin Strategy in Central Non-Small-Cell Lung Cancer.Annals of surgical oncology · 2026Article
- The expert consensus document on minimally invasive upper lobectomy for lung cancer in China.Journal of thoracic disease · 2026Review
- Atypical type D extended sleeve resection after neoadjuvant chemoimmunotherapy in a 69-year-old man with locally advanced lung cancer and a tracheobronchial branching anomaly: a case report.Translational lung cancer research · 2026Article
- Bronchial sleeve lobectomy with pulmonary artery reconstruction following neoadjuvant chemoimmunotherapy: A propensity score-weighted comparison.JTCVS open · 2026Article
- Impact of bronchial anastomosis wrapping on outcomes following sleeve lobectomy.Journal of thoracic disease · 2025Article
- Comparison of robot-assisted and video-assisted thoracic sleeve lobectomy in non-small cell lung cancer: insights from a high-volume center.Journal of thoracic disease · 2025Article
- Risk factors for postoperative pulmonary complications in non-adenocarcinoma non-small cell lung cancer patients undergoing surgery after neoadjuvant therapy.Translational lung cancer research · 2025Article
- Impact of neoadjuvant therapy on angioplastic lobectomy: a retrospective study.Interdisciplinary cardiovascular and thoracic surgery · 2024Article
- Neoadjuvant immunochemotherapy-a promising strategy for primary pulmonary lymphoepithelioma-like carcinoma.World journal of surgical oncology · 2024Article
- Treatment patterns and clinical outcomes of resectable central non-small cell lung cancer patients undergoing sleeve lobectomy: a large-scale, single-center, real-world study.Translational lung cancer research · 2024Article
- Predicting complication risks after sleeve lobectomy for non-small cell lung cancer.Translational lung cancer research · 2024Article
- Extended lobectomy-how minimally invasive can we go?Translational lung cancer research · 2024Article
- Surgery challenges and postoperative complications of lung cancer after neoadjuvant immunotherapy.Thoracic cancer · 2024Article
- Neoadjuvant therapy and sleeve lobectomy for locally advanced non-small cell lung cancer: morbidity and survival balancing.Journal of thoracic disease · 2024Article
- The impact of neoadjuvant therapy on postoperative outcomes following sleeve lobectomy for locally advanced non-small cell lung cancer: a call for future investigation.Journal of thoracic disease · 2024Article
- Resectable non-stage IV nonsmall cell lung cancer: the surgical perspective.European respiratory review : an official journal of the European Respiratory Society · 2024Review
- Minimally invasive surgery role in central squamous lung cancer after neoadjuvant chemoimmunotherapy.Journal of thoracic disease · 2024Article
- Safety and Efficacy of Neoadjuvant Chemoimmunotherapy versus Chemotherapy for Non-Small Cell Lung Cancer Undergoing Sleeve Resection.Cancer management and research · 2024Review
Corrections and comments
- Commented on by
- Commented on by
Authors and funding
8 authors at 2 institutions in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
objectivesTo evaluate the feasibility and safety of sleeve lobectomy after neoadjuvant therapy by assessing the postoperative morbidity.
methodsPatients who underwent sleeve lobectomy for non-small cell lung cancer (NSCLC) were retrospectively analyzed from January 2018 to December 2021. A total of 613 patients were enrolled, including 124 patients who received previous neoadjuvant therapy and 489 patients who did not. Propensity score matching was adopted to create a balanced cohort consisting of 97 paired cases. Patient demographics and perioperative outcomes were compared between the 2 groups, and logistic regression analysis was used to identify risk factors for postoperative complications.
resultsIn the entire cohort, univariable logistic regression analysis showed that smoking history (odds ratio [OR], 1.501; 95% confidence interval [CI], 1.011-2.229, P = .044), open thoracotomy (OR, 1.748; 95% CI, 1.178-2.593, P = .006), and operation time more than 150 minutes (OR, 1.548; 95% CI, 1.029-2.328, P = .036) were risk factors for postoperative complications, and multivariable logistic regression analysis showed open thoracotomy was an independent risk factor (OR, 1.765; 95% CI, 1.178-2.643, P = .006). In the balanced cohort, the neoadjuvant group had a lower proportion of double-sleeve resections (3.1% vs 11.3%, P = .035) and longer postoperative chest tube drainage (6.67 ± 3.81 vs 5.13 ± 3.74 days, P < .001). However, no significant differences were observed in postoperative morbidity between the 2 groups (25.8% vs 24.7%, P = .869). The complete pathologic response of chemoimmunotherapy was significantly superior to chemotherapy alone (28.2% vs 4.1%, P < .001), and no significant differences were noted in postoperative morbidity in different neoadjuvant therapy modalities.
conclusionsAfter neoadjuvant therapy, sleeve lobectomy can be safely performed with no increased postoperative morbidity.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.